 |
市场调查报告书
商品编码
1778487
全球Tacrolimus市场：成长、规模和趋势分析 - 按产品类型、应用和最终用户 - 区域展望、竞争策略和细分市场预测（至 2034 年）Tacrolimus Market Growth, Size, Trends Analysis - By Product Type, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034 |
||||||
根据《全球Tacrolimus市场：成长、规模和趋势分析—按产品类型、应用和最终用户—区域展望、竞争策略和细分预测到 2034 年》报告，全球Tacrolimus市场规模预计到 2034 年将达到 123.5 亿美元，复合年增长率为 5.86%。
Tacrolimus与其他药物合併使用，用于预防肾臟移植患者的排斥反应（免疫系统对移植器官的攻击）。Tacrolimus也与其他药物合併使用，用于预防肝臟、肺部和心臟移植患者的排斥反应。Tacrolimus是一种免疫抑制剂，这意味着它可以抑制免疫系统的活性，防止其损害移植器官。
限制因素：Tacrolimus可引起严重的副作用，例如神经毒性、糖尿病、高血糖、肾毒性、感染疾病和高血压。这些不良副作用常常导致患者停止治疗，限制了Tacrolimus市场的成长。此外，替代药物的供应不足也进一步限制了Tacrolimus市场的成长。
调查范围
报告指标详情
2021年至2034年的市场规模
基准年：2024年
预测期：2025-2034年
目标细分：按产品类型、按应用、按最终用户
涵盖地区：北美、拉丁美洲、亚太地区、欧洲、中东和非洲
目标公司：雅培实验室、安斯泰来製药、Biocon 有限公司、罗氏製药、Glenmark 製药、葛兰素史克、Lupine 製药、诺华、辉瑞、武田製药
全球Tacrolimus市场细分：
按产品类型：全球Tacrolimus市场按产品类型细分为锭剂和胶囊剂、注射剂和其他。
按应用：全球Tacrolimus市场按应用细分为免疫抑制、皮肤炎和其他。
按最终用户划分：全球Tacrolimus市场按最终用户细分为医院、诊所和其他。
区域：包括北美、拉丁美洲、亚太地区、欧洲以及中东和非洲的数据。
目录
第一章 引言
第二章调查方法
第三章执行摘要
第四章 市场动态
- 驱动因素、限制因素、机会与挑战分析
第五章 市场变数与展望
- SWOT分析
- PESTEL分析
- 波特五力分析
- 热图分析
第六章 竞争态势
- 全球Tacrolimus市场：製造地分布、销售区域及产品类型
- 全球Tacrolimus市场的併购、合作伙伴关係、产品发布和合作
7. 2021-2034 年全球Tacrolimus市场（按产品类型划分）（百万美元）
- 锭剂、胶囊
- 注射
- 其他的
8. 全球Tacrolimus市场，按应用划分（百万美元），2021-2034 年
- 免疫抑制
- 皮肤炎
- 其他的
9. 全球Tacrolimus市场，以最终用户划分（百万美元），2021-2034 年
- 医院
- 诊所
- 其他的
第 10 章。 2021-2034 年全球Tacrolimus市场（百万美元）
- 全球Tacrolimus市场规模与市场占有率
第 11 章。 2021 年至 2034 年按地区分類的全球Tacrolimus市场（百万美元）
- 亚太地区
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 其他的
- 欧洲
- 法国
- 德国
- 义大利
- 西班牙
- 英国
- 其他的
- 中东和非洲
- 沙乌地阿拉伯王国
- 阿拉伯聯合大公国
- 卡达
- 南非
- 埃及
- 摩洛哥
- 奈及利亚
- 其他的
- 北美洲
- 加拿大
- 墨西哥
- 美国
- 拉丁美洲
- 阿根廷
- 巴西
- 其他的
第十二章：公司简介
- Abbott Laboratories
- Astellas Pharma Inc
- Biocon Ltd
- F. Hoffmann-La Roche Ltd
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Lupin Pharmaceuticals Ltd
- Novartis
- Pfizer Inc
- Takeda Pharmaceutical Company Limited
- 其他的
第十三章 结论
第 14 章简称列表
第 15 章参考链接
Tacrolimus Market Introduction and Overview
According to SPER market research, 'Global Tacrolimus Market Size- By Product Type, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Tacrolimus Market is predicted to reach 12.35 billion by 2034 with a CAGR of 5.86%.
Tacrolimus is used in combination with other medications to avoid rejection (the immune system's attack on a transplanted organ) in people who have had kidney transplants. Tacrolimus is also used in conjunction with other medications to prevent rejection in recipients of liver, lung, or heart transplants. Tacrolimus is an immunosuppressant. It works by inhibiting immune system activity, preventing it from damaging the transplanted organ.
Restraints: Tacrolimus may result in serious adverse effects, including neurotoxicity, diabetes, hyperglycemia, nephrotoxicity, infection, and hypertension. These unfavourable side effects frequently result in treatment termination, which limits tacrolimus market growth. The market growth for tacrolimus is further constrained by the availability of substitute medications.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Product Type, By Application, By End-User
Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered Abbott Laboratories, Astellas Pharma Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, GSK plc, Lupin Pharmaceuticals Ltd, Novartis, Pfizer Inc, Takeda Pharmaceutical Company Limited.
Global Tacrolimus Market Segmentation:
By Product Type: Based on the Product Type, Global Tacrolimus Market is segmented as; Tablets & Capsules, Injections, Others.
By Application: Based on the Application, Global Tacrolimus Market is segmented as; Immunosuppression, Dermatitis, Others.
By End-User: Based on the End-User, Global Tacrolimus Market is segmented as; Hospitals, Clinics, Others.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Tacrolimus Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tacrolimus Market
7. Global Tacrolimus Market, By Product Type (USD Million) 2021-2034
- 7.1. Tablets & Capsules
- 7.2. Injections
- 7.3. Others
8. Global Tacrolimus Market, By Application (USD Million) 2021-2034
- 8.1. Immunosuppression
- 8.2. Dermatitis
- 8.3. Others
9. Global Tacrolimus Market, By End-User (USD Million) 2021-2034
- 9.1. Hospitals
- 9.2. Clinics
- 9.3. Others
10. Global Tacrolimus Market, (USD Million) 2021-2034
- 10.1. Global Tacrolimus Market Size and Market Share
11. Global Tacrolimus Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Abbott Laboratories
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Astellas Pharma Inc
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Biocon Ltd
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. F. Hoffmann-La Roche Ltd
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Glenmark Pharmaceuticals Ltd
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. GSK plc
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Lupin Pharmaceuticals Ltd
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Novartis
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4 .Recent developments
- 12.9. Pfizer Inc
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Takeda Pharmaceutical Company Limited
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
